89bio, Inc.
89bio, Inc. (ETNB) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · ETNB · as of Jun 8, 2026
Key Statistics
Explore 89bio, Inc. Data
etnb stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 15 · Buy rate: 60.0%
The ETNB analyst consensus is Buy, based on ratings from 15 Wall Street analysts over the past 3 months. The average 12-month price target is $17.17, representing +15.70% upside from the current price of $14.84.
Competitors & Peers
etnb competitorsETNB
AGIO
BEAM
COGT
DNLI
GLPGStock Performance
Full HistoryAbout 89bio, Inc.
89bio, Inc. a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candid…
what is 89bio, inc. · etnb stock overview · 89bio, inc. company profile · who is 89bio, inc. ceo · etnb NASDAQ · 89bio, inc. headquarters · 89bio, inc. business segments
About Stock Overview & Key Data
89bio, Inc. (ETNB) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Nov 11, 2019. As of the latest trading session, ETNB stock price is $14.84, with a market capitalization of $2.2B. The stock has returned +65.07% over the past 12 months and +85.96% year-to-date.
According to 15 Wall Street analysts, the consensus rating for 89bio, Inc. stock is Buy, with an average 12-month price target of $17.17. In fiscal year 2024, 89bio, Inc. reported revenue of — and net income of -$367.1M. For detailed data — including 89bio, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, 89bio, Inc. (ETNB) stock price is $14.84. The stock is traded on NASDAQ under the ticker symbol ETNB. The 52-week range is $4.16 – $15.06.